share_log

Regeneron Presents Eye Treatment Results With EYLEA HD at Vision Research Meeting

Benzinga ·  Apr 29 07:02

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of EYLEA HD (aflibercept) Injection 8 mg. The presentations are part of 14 accepted abstracts on EYLEA HD and EYLEA (aflibercept) Injection 2 mg that will be shared at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting from May 5 to 9 in Seattle.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment